Free Trial
NASDAQ:TRIB

Trinity Biotech Q2 2025 Earnings Report

Trinity Biotech logo
$0.65 -0.03 (-3.70%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$0.66 +0.01 (+0.77%)
As of 06/12/2026 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Trinity Biotech EPS Results

Actual EPS
-$0.32
Consensus EPS
-$1.48
Beat/Miss
Beat by +$1.16
One Year Ago EPS
N/A

Trinity Biotech Revenue Results

Actual Revenue
$9.20 million
Expected Revenue
$10.50 million
Beat/Miss
Missed by -$1.30 million
YoY Revenue Growth
N/A

Trinity Biotech Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Trinity Biotech Earnings Headlines

Trinity Biotech Plc Sponsored ADR Class A
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain.tc pixel
See More Trinity Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trinity Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trinity Biotech and other key companies, straight to your email.

About Trinity Biotech

Trinity Biotech (NASDAQ:TRIB) is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation. In the diabetes segment, Trinity Biotech provides hemoglobin A1c analyzers and glucose monitoring systems. It also offers serological and rapid tests for celiac disease, immunoassays for infectious diseases such as HIV and hepatitis B and C, and assays targeting cardiovascular risk markers. These products are used by hospitals, reference labs and clinics to support diagnosis, treatment monitoring and epidemiological surveillance.

Trinity Biotech serves a worldwide customer base through direct sales operations in North America and Europe, together with a network of distributors in Asia Pacific, Latin America and the Middle East. Its manufacturing sites operate under internationally recognized quality standards, ensuring regulatory compliance across multiple jurisdictions. The company’s global footprint and supply chain infrastructure enable it to respond to regional healthcare needs efficiently.

Supported by an experienced leadership team, Trinity Biotech maintains collaborations with research institutions and healthcare providers to drive innovation in diagnostic testing. Ongoing investment in product development and strategic partnerships underpins the company’s commitment to addressing emerging healthcare challenges and improving patient outcomes around the world.

View Trinity Biotech Profile